| Retrospective, observation study: Quantitative and qualitative effect of ezetimibe and HMG-CoA reductase inhibitors on LDL-cholesterol: are there disappearance thresholds for small, dense LDL and IDL? | |
| | |
MedLine Citation:
|
PMID: 20423317 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Lipid profiles were evaluated for 281 dyslipidemia patients treated with HMG-CoA reductase inhibitors (statins) for 2 years. The efficacy and safety of ezetimibe 10 mg/day one-year add-on therapy were also retrospectively evaluated. The results show that in 281 dyslipidemia patients with a mean low-density lipoprotein-cholesterol (LDL-C) level of 120 mg/dl or greater, ezetimibe 10 mg/day administration reduced LDL-C levels to 90 mg/dl or below. Patients who had been treated with one of six statins (pravastatin, simvastatin, fluvastatin, pitavastatin, atorvastatin, and rosuvastatin) for one year were given ezetimibe add-on therapy for one year, which reduced their LDL-C levels by 18% (pravastatin), 25% (simvastatin), 27% (fluvastatin), 30% (pitavastatin), 29% (atorvastatin), and 31% (rosuvastatin). Also, during the one-year add-on therapy, no severe adverse event was detected. An analysis of associations among lipids during a two-year lipid-lowering pharmacotherapy revealed correlations in a single patient. The correlation was between LDL-C and small, dense LDL as well as mid-band lipoprotein cholesterol. In conclusion, ezetimibe 10mg/day add-on therapy may be safe and effective for treating dislipidemia patients who have been treated with a statin. Moreover, this article discusses the disappearance thresholds for small, dense LDL and intermediate-density lipoprotein (IDL) by using the quantitative analysis of densitometric pattern based on genetic algorithm, which indicated that the major eight subspecies of lipoprotein (VLDL1, VLDL2, IDL1, IDL2, LDL1, LDL2, LDL3, HDL). The thershold for small dense LDL indicates the IDL1 plus IDL2 when LDL2 and LDL3 were not detectable, while the thershold for IDL indicates the LDL1 when IDL1, IDL2 and LDL3 were not detectable. |
| | |
Authors:
|
Ikuo Inoue; Takuya Awata; Shigehiro Katayama |
Related Documents
:
|
18001317 - Setting a new standard in achieving superior efficacy: ezetimibe + simvastatin. 17244877 - Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achievin... 17262137 - Influence of simvastatin on bone regeneration of tibial defects and blood cholesterol l... 10190517 - Efficacy and safety of simvastatin for high-risk hypercholesterolemia. 3411247 - Congruence of individual responsiveness to dietary cholesterol and to saturated fat in ... 15087267 - Chemopreventive effects of melatonin on diethylnitrosamine and phenobarbital-induced he... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Recent patents on cardiovascular drug discovery Volume: 5 ISSN: 2212-3962 ISO Abbreviation: Recent Pat Cardiovasc Drug Discov Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-06-10 Completed Date: 2010-09-23 Revised Date: 2011-11-10 |
Medline Journal Info:
|
Nlm Unique ID: 101263805 Medline TA: Recent Pat Cardiovasc Drug Discov Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 143-52 Citation Subset: IM |
Affiliation:
|
Division of Endcrinology and Diabetics, Saitama Medical University, Saitama, Japan. i1901018@saitama-med.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Azetidines / adverse effects, therapeutic use* Cholesterol, LDL / blood* Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects, therapeutic use* Hypercholesterolemia / blood, drug therapy* Lipoproteins, IDL / blood* Lipoproteins, LDL / blood* Male Middle Aged Retrospective Studies |
| Chemical | |
Reg. No./Substance:
|
0/Azetidines; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipoproteins, IDL; 0/Lipoproteins, LDL; 163222-33-1/ezetimibe |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hypofractionated Radiotherapy in Non Small Cell Lung Cancer. A Review of the Current Literature.
Next Document: Both OB folds of single-stranded DNA-binding protein are essential for its ssDNA binding activity in...